ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Thyroid Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1602202
Impaired Sensitivity to Thyroid Hormones is Associated with ASCVD Risk Factors in Beijing in Euthyroid Population: A Cross-Sectional Study
Provisionally accepted
- PLA Strategic Support Force Characteristic Medical Center, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
1) Background: This review aims to investigate the relationship between impaired sensitivity to thyroid hormones and ASCVD risk factors in the euthyroid population. (2) Methods:A cross-sectional study including 7,895 euthyroid subjects aged ≥18 years old was conducted.Height, body weight, blood pressure (BP) were measured, and serum concentrations of lipids, fasting blood glucose, uric acid, free thyroxine (FT4), free triiodothyronine (FT3), and thyrotropin (TSH) were assayed. Thyroid hormone resistance was calculated by Thyroid-stimulating hormone (TSHI), Thyroid Feedback Quantile-based Index (TFQI), and Free Triiodothyronine/Free thyroxine (FT3/FT4), which were calculated based on FT3, FT4, and TSH. (3) Results: We are divided into four groups according to the TFQI quartile. Age, BMI, BP, HDL-C, TC, TG, FBG, UA were statistically significant between the four groups. F3/F4 showed statistical significance in populations with high UA, high FBG, and high TG; TFQI was positively correlated with BP, TG, FBG, UA and TyG, SBP, FBG, UA and TyG, FT3/FT4 was negatively correlated with DBP, SBP, TC, TG and UA. (4) Conclusion: Impaired sensitivity to thyroid hormone in euthyroid population is associated with ASCVD risk factors. These findings are potentially useful for understanding the interaction between thyroid hormone sensitivity and ASCVD risk factors in euthyroid population.
Keywords: Thyroid hormones resistance, Atherosclerotic cardiovascular disease, Dyslipidemia, Uric Acid, Blood Pressure
Received: 29 Mar 2025; Accepted: 30 Jun 2025.
Copyright: © 2025 Shi, Wang, Yang, Zhao, Zhang, Yu, Ni, Liu and Jia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yu Liu, PLA Strategic Support Force Characteristic Medical Center, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.